Patents by Inventor ALVERNIA FRANCESCA SETIADI

ALVERNIA FRANCESCA SETIADI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240410009
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Application
    Filed: August 26, 2024
    Publication date: December 12, 2024
    Applicant: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • Patent number: 12098426
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 24, 2024
    Assignee: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • Publication number: 20220098668
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 31, 2022
    Applicant: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • Patent number: 11236391
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • Publication number: 20200103418
    Abstract: The present invention provides diagnostic and therapeutic methods and compositions for treating a patient suffering from an interleukin-1 receptor-associated kinase 4 (IRAK4)-mediated disorder or condition, such as an immune disorder (e.g., systemic lupus erythematosus (SLE)) or an inflammatory disorder (e.g., asthma). The invention provides diagnostic methods of monitoring the response of a patient having an IRAK4-mediated disorder or condition to treatment including an IRAK4 pathway inhibitor, methods of identifying a patient having an IRAK4-mediated disorder or condition who may benefit from treatment including an IRAK4 pathway inhibitor, and methods of selecting a therapy for a patient having an IRAK4-mediated disorder or condition based on the expression level of one or more IRAK4 biomarkers (e.g., one or more genes set forth in Table 1). Related therapeutic methods and compositions (e.g., diagnostic kits) are also provided.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 2, 2020
    Inventors: Jason HACKNEY, Alvernia Francesca SETIADI, Michael TOWNSEND, Ali A. ZARRIN
  • Publication number: 20180080080
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Application
    Filed: July 27, 2017
    Publication date: March 22, 2018
    Applicant: Genentech, Inc.
    Inventors: MICHAEL TOWNSEND, ALVERNIA FRANCESCA SETIADI, TRACY STATON